TY - JOUR T1 - Additional therapy of COPD patients with respiratory muscles dysfunction JF - European Respiratory Journal JO - Eur Respir J VL - 44 IS - Suppl 58 SP - P3605 AU - Yuliia Huba AU - Olena Myronenko Y1 - 2014/09/01 UR - http://erj.ersjournals.com/content/44/Suppl_58/P3605.abstract N2 - Dihydropyridine calcium antagonists (CA), primarily act on smooth muscles of arteries, i.e. are typical peripheral vasodilators, reducing the pressure in the pulmonary artery. CA also able to reduce the synthesis of matrix metalloproteinase (MMP). One of the positive effects realized through positive employmenton the respiratory muscles (RM).The aim of the study was to evaluate effect of different therapy for COPD pts with RM dysfunction.Material. COPD patients with II stage were divided in to 4 groups:1st (berodual 2 puff 3 times per day) - 12 pts, 2nd (tiotropium 18 μg once daily) – 14 pts, 3d (formoteroly fumarat 12 μg twice daily) – 10 pts, 4th (berodual+amlodipini 5 mg) – 16 pts.Methods. Spirometry and pneumotonometry were performed by means MasterScreen Body/Diff (“Jaeger”, German). FEV1, PImax, PEmax and P0.1 were evaluated.Results. No significant differences in the level of FEV1, PEmax and P0.1 in groups of observations were observed either at baseline or at the end of treatment. Changes of PImax was determined as provide marker of RM dysfunction for COPD pts. Significant increase of PImax has been established in all groups, determination of growth was conducted using a paired Wilcoxon test (p<0,05).Conclusion. The most considerable improvement of inspiratory muscles strength was revealed in the group treated with amlodipini besilat. But therapy with LABA is demonstrate very good effect on level of PImax. ER -